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Abstract
Critically ill patients are often treated with continuous intravenous
infusions of sedative drugs. However, this is associated with high
risk for over-sedation, which can result in prolonged stay in the
intensive care unit. Recently introduced protocols (daily interrup-
tion and analgosedation) have proven to reduce the length of
intensive care unit stay. To introduce these protocols, new agents
or new regimens with the well established agents may be required.
In this article we briefly discuss these new regimens and new
agents, focusing on the short-acting substances.
Introduction
Critically ill patients are often uncomfortable because of pain,
anxiety, and reluctance to undergo mechanical ventilation.
This discomfort is treated with continuous sedation, usually in
combination with an opioid at low dose. However, continuous
sedation has been associated with prolonged mechanical
ventilation and a longer stay in the intensive care unit (ICU),
whereas daily interruption of sedative treatment has been
shown to reduce the duration of mechanical ventilation and
ICU stay [1]. Therefore, a shift from deep to light sedation is
currently recommended. In addition, recent studies suggest
that analgesia-based sedation protocols are as effective as
conventional hypnotic-based sedation protocols but that the
required dose of hypnotic drug is reduced [2,3].
Thus, meeting the goals of analgesia and sedation in the ICU
may require a change in both protocols and drugs used. In
this review we discuss the most commonly used drugs in the
ICU, focusing on the short-acting agents.
Analgesia
Analgesia should be titrated to the needs of the individual
patient. This individual treatment plan usually consists of a
basal regimen that is adapted to the patient’s pain perception
and general features (age, body mass, and so on), in
combination with a rescue dose for incidental and procedural
pain. Analgesics can be administered by enteral, trans-
cutaneous and parenteral routes. However, delayed gastric
emptying, (continuous) gastric drainage, decreased gut func-
tion, uncertain first-pass effect, general edema, and use of
vasopressors, usually make the parenteral route preferable in
critically ill patients. Parenteral drugs can be given by
continuous infusion, bolus and patient-controlled analgesic
techniques. In addition, epidural infusions of local anes-
thetics, often combined with opioids, can provide effective
analgesia, for example in the case of fractured ribs or thoracic
or abdominal wounds.
Epidural analgesia
Epidural analgesia is used extensively in modern anesthetic
practice. A meta-analysis of more than 5,000 surgical
patients [4] has shown that postoperative epidural analgesia
reduces time to extubation, ICU stay, incidence of renal
failure, morphine consumption during the first 24 hours, and
maximal glucose and cortisol blood concentrations, and
improves forced vital capacity. Many of these benefits may
also be relevant to ICU patients, as has been demonstrated
for cardiac surgical [5] and thoracic trauma [6] patients. The
effectiveness and safety of epidural analgesia has also been
demonstrated in critically ill patients with severe acute
pancreatitis [7]. However, whether sepsis, with or without
positive blood cultures, is an absolute contraindication for the
use of epidural analgesia is still a matter of debate. Further
research is therefore required to define the role of epidural
analgesia in this high-risk group [8].
Opioids
Opioids remain the mainstay drug for analgesic therapy in the
ICU patient [9]. Opioids act selectively on neurons that
transmit and modulate nociception, leaving other sensory
modalities and motor functions intact. Opioid receptors are
found in the brain, spinal cord, and peripheral tissues. All
opioids depress respiratory drive in a dose-dependent manner,
and this depression is increased when opioids are given in
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combination with benzodiazepines. In general, opioids have
minimal hemodynamic effects in euvolemic patients. Depen-
dence and withdrawal effects can occur with prolonged
continuous infusion of opioids.
Morphine
Morphine is the oldest opioid in current use, being dis-
covered almost 200 years ago, and it is the most hydrophilic
of the opioids. The dose required to produce analgesia varies
markedly and depends on factors such as tolerance, and
metabolic and excretory ability. Hepatic metabolism produces
80% morphine-3-glucuronide (which has no analgesic action
or neurotoxicity) and 20% morphine-6-glucuronide. The latter
is a potent analgesic, having 20 to 40 times the activity of
morphine [10,11]. Both metabolites are eliminated by the
kidney and may therefore accumulate in patients with renal
dysfunction. For this reason, fentanyl is preferred in patients
with renal insufficiency [12]. Morphine-induced histamine
release is rarely clinically important in ICU patients.
Fentanyl and remifentanil
Fentanyl and sufentanil are fat soluble and therefore have a
rapid onset of action. However, increased fat solubility also
results in increased volume of distribution, thereby increasing
the risks for accumulation and delayed recovery after pro-
longed administration. In contrast, remifentanil (a derivative of
fentanyl) is a short-acting opioid with unique properties.
Remifentanil is metabolized by unspecific esterases that are
widespread throughout the plasma, red blood cells, and
interstitial tissues, whereas elimination of other opioids
requires hepatic biotransformation and renal excretion. The
context-sensitive half-time (the time required for the drug’s
plasma concentration to decrease by 50% after cessation of
an infusion) of remifentanil is consistently short (3.2 minutes),
even after an infusion of long duration (>8 hours) [13].
Therefore, analgesia-based sedation with remifentanil has
been introduced as an option in ICU patients.
Muellejans and colleagues [14] compared the efficacy and
safety of remifentanil and fentanyl in postsurgical ICU patients.
Both agents were effective in achieving the targeted sedation
level and recovery was rapid, without any apparent difference
between agents. In contrast, in their comparison of a
remifentanil-based versus a morphine-based regimen under
similar conditions, Dahaba and coworkers [15] found that the
mean duration of mechanical ventilation and extubation time
were significantly shorter in the remifentanil group. In critically
ill patients requiring prolonged mechanical ventilation for up
to 10 days, Breen and colleagues [16] compared an analgo-
sedation regimen using remifentanil versus a midazolam-
based sedation regimen to which fentanyl or morphine was
added for analgesia. The remifentanil-based sedation regimen
was associated with significantly reduced duration of
mechanical ventilation by more than 2 days. Although remi-
fentanil is only licensed for up to 3 days of use in the ICU, it
has been demonstrated even in such ICU patients (with an
expected duration of mechanical ventilation of 2 to 3 days)
that remifentanil-based analgosedation significantly decreases
the duration of mechanical ventilation and length of ICU stay
[17]. In addition, remifentanil does not exert significantly
prolonged clinical effects when it is administered to ICU
patients with renal failure [18,19]. Based on these studies, it
can be concluded that remifentanil is effective for providing
both analgesia and sedation in critically ill patients, even
those suffering from multiple organ failure.
Sedation
A widely accepted theory regarding the action of anesthetics
is that they interact with the inhibitory γ-aminobutyric acid
(GABA) neurotransmitter system. The GABA and adrenergic
neurotransmitter systems counterbalance the action of
excitatory neurotransmitters. Hypnotic drugs interact with
different components of the GABA receptor complex (Fig. 1).
Benzodiazepines
Benzodiazepines bind to a specific receptor site of the GABA
receptor, and thus the degree of modulation is limited, which
explains the ‘ceiling effect’ of their central nervous system
(CNS) depression. It has been suggested that a benzo-
diazepine receptor occupancy of 20% provides anxiolysis,
whereas an occupancy of 30% to 50% is associated with
sedation, and 60% is required for hypnosis [20]. Benzodiaze-
pines produce dose-dependent respiratory depression. In
healthy patients, respiratory depression is moderate but
depression is enhanced in patients with chronic respiratory
disease, and synergistic depressant effects occur when
benzodiazepines are combined with opioids.
Midazolam and lorazepam are the most commonly used
benzodiazepines for ICU sedation [9]. Midazolam is a short-
acting, water-soluble benzodiazepine that undergoes exten-
sive oxidation in the liver via the cytochrome P450 enzyme
system to form water-soluble hydroxylated metabolites, which
are excreted in urine. However, the primary metabolite,
namely 1-hydroxymethylmidazolam, has mild CNS depressant
activity and may accumulate in the critically ill patient,
especially in the case of kidney failure. Medications that
interfere with the cytochrome P450 enzyme (for example,
erythromycin, calcium channel blockers, and itraconzole) will
decrease metabolization of midazolam. Lorazepam is a long-
acting benzodiazepine that is metabolized by hepatic
glucuronidation to inactive metabolites that are cleared by the
kidneys. Hepatic dysfunction has greater impact on oxidation
than glucuronidation.
During short-term infusions, both lorazepam and midazolam
are generally safe and effective sedative agents. However,
during continuous infusions accumulation of midazolam can
occur because of the large volume distribution and its high
lipophilicity. High-dose lorazepam treatment carries a risk for
toxicity from propylene glycol, a vehicle that is used for
solubility in the intravenous solution. It should be consideredPage 3 of 5
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whenever a patient exhibits an unexplained anion gap,
unexplained metabolic acidosis, hyperosmolality, and/or
clinical deterioration [21]. In addition, lorazepam has been
found to be an independent risk factor for transition of ICU
patients into delirium [22].
Barr and colleagues [23] investigated the pharmacokinetics
and pharmacodynamics of midazolam and lorazepam adminis-
tered as continuous intravenous infusions for postoperative
sedation in surgical ICU patients. During the maintenance
period of sedation, patients in the lorazepam group were
optimally sedated (Ramsay Sedation Scale score 3 or 4) only
49% of the time, as compared with 69% of the time for
midazolam. Patients receiving lorazepam were also more often
deeply sedated (Ramsay Sedation Scale score 5 or 6) than
those receiving midazolam. Patents who received lorazepam
emerged from sedation more slowly and underwent extubation
much later than did patients receiving midazolam (8.7 hours
versus 3 hours and 21.2 hours versus 5.4 hours, respectively).
It was also shown that older patients required much lower
plasma concentrations of benzodiazepine to achieve levels of
sedation comparable to those in younger patients.
Propofol
Propofol is a unique sedative-hypnotic agent with a rapid
onset and offset of action. Like the benzodiazepines, propofol
acts on the GABA receptor, although the site of action on
this receptor is different (Fig. 1). Propofol is hydrophobic and
so it is formulated in an oil-in-water emulsion. Pain at the
injection site occurs in up to two-thirds of patients when
propofol is injected into small veins.
The lipophilic properties of propofol allow it to cross the blood-
brain barrier rapidly. Metabolism of propofol occurs primarily by
conjugation in the liver to inactive metabolites, which are
eliminated by the kidneys. Hepatic and renal diseases have
little impact on the pharmacokinetics of propofol. Hypotension
attributed to systemic vasodilation is a well known adverse
effect of propofol, especially in hypovolemic patients. Hyper-
triglyceridemia in ICU patients receiving propofol infusions
occurs rarely and is typically associated with high propofol
infusion rates, concurrent administration of parenteral lipids for
nutrition, or baseline hypertriglyceridemia. Propofol infusion
syndrome is a rare but serious and potentially fatal adverse
effect, typically seen with infusion rates >5 mg/kg/h for more
than 48 hours [24]. This syndrome is characterized by dys-
arhythmias, heart failure, metabolic acidosis, hyperkalemia and
rhabdomyolysis, and it carries a mortality rate of up to 85%.
The pathophysiology of this syndrome is currently unclear, but
it has been speculated that a combination of high-dose
propofol with endogenous as well as exogenously administered
catecholamines and/or glucocorticoids may act as a trigger.
Treatment consists of immediate cessation of propofol
administration, and correction of hemodynamic and metabolic
abnormalities. In order to minimize the risk for this syndrome,
propofol dosage should be under 4 mg/kg per hour for a
maximum of 7 days [24]. Like benzodiazepines, propofol also
appears to be an effective anticonvulsant.
The pharmacokinetics of propofol in critically ill patients
depend on various factors. Barr and colleagues [25] studied
the pharmacology of propofol infusions in ICU patients and
demonstrated that the offset of sedation varies considerably,
being a function of depth of sedation, duration of the infusion,
and patient size and body composition. By integrating the
results of the studied patients, they developed a dosing
regimen for propofol sedation in ICU patients. For a typical
ICU patient, the emergence times from light sedation (to
decrease the Ramsey Sedation Scale score from 3 to 2)
remained fairly rapid (<35 minutes) for propofol infusions
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Figure 1
Functional binding sites on the GABA receptor. Adapted from the PACT Sedation module (European Society of Intensive Care Medicine
www.esicm.org). Reprinted from Richards G, Schoch P, Haefely W: Benzodiazepine receptors: new vistas. Seminars in Neuroscience 1991,
3:191-203. © 1991 with permission from Elsevier.lasting 3 days or less. For infusions lasting up to 14 days, the
emergence time was 3.5 hours. In contrast, the emergence
times from deep sedation (to decrease the Ramsey Sedation
Scale score from 5 to 2) was 25 hours for a 24-hour infusion,
and increased to about 3 days for propofol infusions lasting 7
to 14 days.
In a meta-analysis, Ostermann and colleagues [26] included
32 studies of sedation in the ICU (20 studies on short-term
and 14 studies on long-term sedation). They found that
propofol was at least as effective for sedation as was
midazolam, and resulted in a shorter interval to extubation, but
it was associated with increased risk for hypotension and
higher cost. In contrast, Kress and coworkers [1] found no
difference in the duration of mechanical ventilation and length
of stay in the ICU or hospital between midazolam and
propofol in mechanically ventilated ICU patients. One year
later, the results of a multicenter trial conducted in four
Canadian ICUs were published [27]; in this trial sedation with
propofol was compared with midazolam sedation in critically
ill patients. They found that propofol sedation allowed for
more rapid tracheal extubation than when midazolam
sedation was used but this did not result in earlier ICU
discharge. Comparative studies evaluating the ability of
propofol sedation to accelerate ICU discharge have yielded
contradictory results. The reason for this is not yet known
and randomized controlled trials are warranted.
Dexmedetomidine
Dexmedetomidine is a centrally acting α2-agonist with
sedative and analgesic properties; it is similar to clonidine but
has much greater α2 to  α1 binding affinity. The sedative
properties are facilitated through the locus coeruleus site in
the CNS, and the analgesic effects may occur via activation
of the α2 receptors by accentuating the action of opioids
[28]. This class of drugs causes no significant effect on
respiratory drive, even when used with opioids. Dexmedeto-
midine has a biphasic effect on the cardiovascular system.
The initial bolus injection is associated with vasoconstrictive
effects, causing bradycardia and hypertension. Continuous
infusion is associated with hypotension secondary to
vasodilation caused by central sympatholysis.
Most studies involving dexmedetomidine have evaluated
postoperative ICU patients and demonstrated efficacy for
short-term sedation and analgesic sparing [29]. Although
dexmedetomidine is labeled in some countries only for
sedation of less than 24 hours, the drug has not been
extensively studied as an agent for long-term administration to
critically ill, mechanically ventilated patients [30].
Volatile sedation
Isoflurane has successfully been used for sedation in ventilator-
dependent ICU patients. Several studies compared isoflurane
with midazolam or with propofol [31-33] and found adequate
sedation with predictable and quick awakening, without
reported tolerance or withdrawal symptoms. Initially, the lack
of necessary equipment led to limited use of volatile
anesthetics as sedative agents in the ICU, but technologic
advances, especially the introduction of the AnaConDa® filter
(Hudson RCI, Uppsland Väsby, Sweden), have greatly simpli-
fied administration of volatile anesthetic agents in this setting.
This device is connected between the patient and a normal
ICU ventilator, and it maintains 90% of the volatile anesthetic
inside the patient, analogous to the action of a heat-moisture
exchanger [34]. It has been shown that isoflurane inhalation
via this device was a safe and effective method of sedation in
ICU patients, with significantly shorter awakening times
(<25 minutes) compared with midazolam (range 57 to
837 minutes) [35]. Although volatile anesthetics are not
licensed for use for sedation in the ICU, volatile sedation in
the ICU appears a promising alternative to intravenous
sedatives for mechanically ventilated adult patients in the
ICU, but more clinical studies are warranted.
Conclusion
It appears that optimizing analgesia and sedation protocols is
more important than seeking the ideal agent. The ideal
regimen would provide adequate pain control and be easy to
titrate, with a rapid onset and offset of action and without
accumulation; it should also be cost-effective by improving
quality of care, reducing the time spent on mechanical
ventilation, or reducing the length of stay in the ICU. At
present, none of the agents currently in use fulfills all of these
requirements. In changing from deep to light sedation and from
hypnotic-based to analgesic-based sedation, a short-acting
opioid may be of importance. In addition, a relatively new agent
for ICU sedation, the α2-agonist dexmedetomidine, is promising
because of its combination of sedative and analgesic proper-
ties but with less effect on respiratory drive. However, we
currently lack efficacy and safety data for longer dexmedeto-
midine infusions. Inhalational sedation may also be advantageous
in ICU sedation. For example, isoflurane is among the safest
anesthetic drugs, with almost complete elimination via exhala-
tion after administration is discontinued [36]. It is therefore
independent of renal or liver function, which may be of
particular importance in ICU sedation. Despite new devices for
use of volatile anesthetics in the ICU, more studies are needed
to confirm their efficacy and safety. Thus, clinicians should
continue to search for the optimal regimen, using both new and
old agents in various combinations.
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